Skip to main content

Table 3 Stage-specific three-year relative survival of patients with small cell lung carcinoma and extrapulmonary small cell carcinoma diagnosed in SEER-13 according to gender, age, and calendar year, 1992-2010*

From: A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992–2010

 

SCLC

EPSCC

EPSCC-to-SCLC

Stage

No.

RS (%)

(95%CI)

No.

RS (%)

(95%CI)

RSR

(95%CI)

Total

        

Limited

12,070

20.7

(19.9, 21.5)

907

42.7

(39.1, 46.2)

2.06

(1.88, 2.26)‡

Distant

29,003

4.0

(3.7, 4.2)

835

6.2

(4.6, 8.1)

1.55

(1.16, 2.07)‡

Gender and age

Males, <60 years

 Limited

1,407

24.9

(22.6, 27.3)

124

37.0

(28.2, 45.7)

1.49

(1.15, 1.92)‡

 Distant

3,993

4.8

(4.2, 5.5)

121

7.8

(3.8, 13.6)

1.63

(0.85, 3.11)

Females, <60 years

 Limited

1,442

31.2

(28.7, 33.7)

251

51.8

(45.2, 58.1)

1.66

(1.43, 1.93)‡

 Distant

3,043

7.2

(6.2, 8.1)

169

11.1

(6.7, 16.8)

1.54

(0.96, 2.49)

Males, ≥60 years

 Limited

4,469

16.8

(15.6, 18.0)

312

40.3

(34.0, 46.6)

2.40

(2.02, 2.85)‡

 Distant

11,594

2.8

(2.5, 3.1)

297

3.7

(1.8, 6.7)

1.32

(0.69, 2.53)

Females, ≥60 years

 Limited

4,752

19.7

(18.5, 21.0)

220

38.8

(31.6, 45.9)

1.97

(1.62, 2.40)‡

 Distant

10,373

4.0

(3.6, 4.4)

248

4.9

(2.6, 8.4)

1.23

(0.67, 2.25)

Race and age

Whites, <60 years

 Limited

2,360

28.9

(27.1, 30.8)

282

47.0

(40.8, 52.9)

1.63

(1.41, 1.88)‡

 Distant

5,849

5.7

(5.1, 6.4)

224

10.1

(6.5, 14.7)

1.77

(1.16, 2.70)‡

Blacks, <60 years

 Limited

327

21.3

(16.9, 26.1)

44

25.1

(13.3, 38.9)

1.18

(0.67, 2.08)

 Distant

796

5.1

(3.7, 6.9)

36

10.7

(3.2, 23.5)

2.10

(0.76, 5.81)

Whites, ≥60 years

 Limited

7,887

18.5

(17.6, 19.4)

449

38.7

(33.4, 43.8)

2.09

(1.81, 2.42)‡

 Distant

18,793

3.3

(3.0, 3.6)

451

4.5

(2.7, 7.0)

1.36

(0.84, 2.21)

Blacks, ≥60 years

 Limited

699

16.5

(13.6, 19.6)

41

47.5

(30.6, 62.6)

2.88

(1.95, 4.25)‡

 Distant

1,770

3.2

(2.4, 4.2)

50

4.3

(0.8, 13.1)

1.34

(0.33, 5.46)

Primary tumor size

≤3 cm

 Limited

2,930

29.2

(27.5, 31.0)

187

57.1

(48.8, 64.6)

1.96

(1.68, 2.27)‡

 Distant

4,469

5.5

(4.8, 6.2)

67

11.3

(4.7, 20.9)

2.05

(0.98, 4.32)

>3 cm - ≤7 cm

 Limited

3,391

21.6

(20.1, 23.1)

255

38.9

(32.3, 45.3)

1.80

(1.50, 2.16)‡

 Distant

6,817

4.2

(3.7, 4.7)

210

3.7

(1.6, 7.0)

0.88

(0.41, 1.87)

>7 cm

 Limited

1,071

15.6

(13.3, 18.0)

117

37.0

(27.8, 46.3)

2.37

(1.76, 3.19)‡

 Distant

3,079

4.9

(4.1, 5.7)

135

12.6

(7.3, 19.5)

2.57

(1.55, 4.27)‡

Year of diagnosis

1992-2000

 Limited

6,660

18.9

(17.9, 19.9)

364

40.9

(35.5, 46.3)

2.16

(1.87, 2.50)‡

 Distant

14,006

3.5

(3.2, 3.8)

314

5.5

(3.2, 8.5)

1.57

(0.98, 2.53)

2001-2010

 Limited

5,410

23.0

(21.7, 24.2)

543

43.8

(39.1, 48.4)

1.90

(1.69, 2.14)‡

 Distant

14,997

4.4

(4.1, 4.8)

521

6.7

(4.6, 9.3)

1.52

(1.06, 2.19)‡

  1. Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, No. number, RS relative survival, RSR RS ratio, SCLC small cell lung carcinoma, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results (SEER) Program.
  2. * Based on microscopically confirmed cases of small cell carcinoma diagnosed during 1992–2010 and followed through 2011. To allow a general overview of stage across primary sites, we used the SEER historic stage variable that includes localized (confined to the organ of origin), regional (direct extension to adjacent organ/tissue or regional lymph nodes), distant (discontinuous metastases), and unspecified stages. We combined localized and regional stages into the category of “limited” stage and maintained the distant stage variable as defined in the SEER Program.
  3. Stage was not specified for 1,760 cases of SCLC (3-year RS (%) = 12.1, 95 % CI = 10.5, 13.8), and 162 cases of EPSCC (3-year RS (%) = 21.0, 95 % CI = 14.6, 28.2).
  4. ‡ 95 % CI excludes 1.00 (based on unrounded upper and lower CI), and RSR is significant (P < 0.05).